GENELUX CORP ($NASDAQ:GNLX) reported their Q3 2023 earnings results on November 14, with revenues of USD 0.0 million, representing a decrease of 100.0% year-over-year. Net income for the quarter was reported to be USD -5.3 million, compared to the 4.9 million from the same period in the prior year.
On Tuesday, GENELUX CORP reported positive earnings results for FY2023 Q3, with their stock opening at $14.1 and closing at $14.6, up 3.0% from the prior closing price of 14.2. This is the company’s sixth consecutive quarter of positive growth, a sure sign that their investments are continuing to pay off. The results exceeded expectations and investors responded positively, pushing up the stock’s price by 3.0%. This strong performance is largely due to GENELUX CORP’s diversified portfolio of investments and their commitment to developing innovative solutions to meet the needs of customers.
The company also reported that they are continuing to invest in new technologies and expanding into new markets as they strive to remain competitive in a rapidly changing industry. With these investments, GENELUX CORP is well-positioned to continue its success and deliver positive results to shareholders in the future. Live Quote…
About the Company
Ownership (Institutional/ Fund Holdings)
Below shows the total revenue, net income and net margin for Genelux Corp. More…
Income Statement Reports (Yearly/ Quarterly/ LTM)
Cash Flow Snapshot
Below shows the cash from operations, investing and financing for Genelux Corp. More…
Cash Flow Statement (Yearly/ Quarterly/ LTM)
Cash Flow Supplement
Balance Sheet Snapshot
Below shows the total assets, liabilities and book value per share for Genelux Corp. More…
Balance Sheet (Yearly/ Quarterly)
Balance Sheet Supplement
||Book Value Per Share
Key Ratios Snapshot
Some of the financial key ratios for Genelux Corp are shown below. More…
Income Statement Ratios
Balance Sheet Ratios
Cash Flow Ratios
Other Supplementary Items
|3Y Rev Growth
||3Y Operating Profit Growth
Analysis – Genelux Corp Intrinsic Stock Value
At GoodWhale, we have conducted a comprehensive analysis of GENELUX CORP‘s fundamentals. Our proprietary Valuation Line indicated that the fair value of the GENELUX CORP share is approximately $10.5. However, the stock is currently trading at $14.6, representing an overvaluation of 38.7%. We believe that investors should be aware of this discrepancy before investing in the stock. More…
Star Chart Analysis
Founded in 2001, it has established itself as a leader in the field, competing with companies such as Resverlogix Corp, 180 Life Sciences Corp, and Cyclerion Therapeutics Inc. All four companies are dedicated to the advancement of cancer treatments and prevention and have worked together towards a common goal of improving patient outcomes.
– Resverlogix Corp ($TSX:RVX)
Resverlogix Corp is a biopharmaceutical company that focuses on the development of novel therapeutics for cardiovascular diseases. The company has a market cap of 32.14M as of 2023, which reflects the overall value of the business and its stock price. Its Return on Equity (ROE) is 2.05%, which shows that the company is generating a small return on its invested capital. This suggests that there is room for improvement in terms of increasing profitability. The company has been actively investing in research and development in order to develop novel therapeutics, which could potentially lead to improved financial performance in the future.
– 180 Life Sciences Corp ($NASDAQ:ATNF)
180 Life Sciences Corp is a biotechnology company based in California that focuses on developing next-generation treatments and cures for diseases and conditions in the human body. The company has a market cap of 6.97 million as of 2023, indicating it is a small-cap firm. Additionally, its Return on Equity (ROE) is -310.84%, indicating the company is not currently generating positive returns for investors. This could be due to its heavy investment in research and development, or because its new treatments have yet to be approved by regulatory bodies such as the FDA. The company is likely hoping to transition from a negative ROE to a positive one in the future with more successful treatments and products.
– Cyclerion Therapeutics Inc ($NASDAQ:CYCN)
Cyclerion Therapeutics Inc is a biopharmaceutical company specializing in the development of treatments for diseases related to the central nervous system. The company has a market cap of 9.47 million dollars as of 2023, indicating a relatively small size compared to most biopharmaceutical firms. Unfortunately, the company’s return on equity (ROE) is a negative 334.13%, which suggests the company has not been able to generate a profit from its investments or equity mainly due to the high expense associated with research and clinical trials. Despite this, the company has made progress in developing new treatments and their market cap could increase in the future as investors develop more confidence in their products.
Investors should take note of the GENELUX CORP Q3 FY2023 earnings, which saw total revenue of USD 0.0 million and a year-over-year decrease of 100.0%. Net income for the quarter was reported to be USD -5.3 million, compared to the previous year’s net income of 4.9 million. Despite the drop in net income, the stock price moved up the same day, indicating that investors are still optimistic about the company’s future prospects. While careful research and analysis of the company is recommended before investing, signs suggest that GENELUX CORP may present a good opportunity for investors.